Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)

Bibliographic Details
Title: Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)
Authors: Xinghao Ai, Bo Jia, Zhiyi He, Junping Zhang, Minglei Zhuo, Jun Zhao, Zhe Wang, Jiexia Zhang, Zaiwen Fan, Xiaotong Zhang, Chong Li, Feng Jin, Ziming Li, Xia Ma, Hao Tang, Xiang Yan, Wei Li, Yuanyuan Xiong, Huan Yin, Rongrong Chen, Shun Lu
Source: Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-10 (2024)
Publisher Information: Nature Publishing Group, 2024.
Publication Year: 2024
Collection: LCC:Medicine
LCC:Biology (General)
Subject Terms: Medicine, Biology (General), QH301-705.5
More Details: Abstract Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for patients with non-small cell lung cancer (NSCLC). In spite of durable responses in some patients, many patients develop early disease progression during the ICI treatment. Thus, early identification of patients with no durable benefit would facilitate the clinical decision for these patients. In this prospective, multicenter study, 101 non-EGFR/ALK patients who received ICI treatment were enrolled after screening 328 stage III-IV NSCLC patients. At the date of cutoff, 83 patients were eligible for ICI efficacy evaluation, with 56 patients having progress-free survival (PFS) over 6 months, which was defined as durable clinical benefit (DCB). A multimodal model was established by integrating normalized bTMB, early dynamic of ctDNA and the first RECIST response. This model could robustly predict DCB with area under the curve (AUC) of 0.878, sensitivity of 79.2% at 86.4% specificity (accuracy = 80.0%). This model was further validated in the independent cohort of the DIREct-On study with AUC of 0.887, sensitivity of 94.7% at 85.3% specificity (accuracy = 90.3%). Patients with higher predict scores had substantially longer PFS than those with lower scores (training cohort: median PFS 13.6 vs 4.2 months, P
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2059-3635
Relation: https://doaj.org/toc/2059-3635
DOI: 10.1038/s41392-024-02060-3
Access URL: https://doaj.org/article/cf019c528e76433f8ef73b45a9633f44
Accession Number: edsdoj.f019c528e76433f8ef73b45a9633f44
Database: Directory of Open Access Journals
More Details
ISSN:20593635
DOI:10.1038/s41392-024-02060-3
Published in:Signal Transduction and Targeted Therapy
Language:English